ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. 

Biotechnology

ALX Oncology

Jaume Pons

Sue Naim

Yeong-Liang Lin

Marija Vrljic

Hadi Falahatpisheh

Sophia Randolph

Peter García

Hank Stern

Susan Vermeir

Chris Byrd

Athanasios Tsiatis

Michael Chang

Jeanne Jew

The executive team at ALX Oncology has a history of experience in the oncology industry, with several members coming from Pfizer and Merck Inc. They have also worked as scientists, controllers, and CFOs at various companies. They have a variety of educational backgrounds, including protein engineering, finance, economics, accounting, and biochemistry.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at ALX Oncology

Leadership Team

Board of Directors